Chemicals
Compare Stocks
5 / 10Stock Comparison
ORGN vs BIOX vs PGEN vs GEVO vs LOOP
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
Biotechnology
Chemicals - Specialty
Chemicals - Specialty
ORGN vs BIOX vs PGEN vs GEVO vs LOOP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals | Agricultural Inputs | Biotechnology | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $211M | $30M | $1.22B | $493M | $68M |
| Revenue (TTM) | $25M | $318M | $6M | $174M | $11M |
| Net Income (TTM) | $-69M | $-53M | $-247M | $-11M | $-3M |
| Gross Margin | 1.8% | 39.1% | 23.0% | 23.4% | 96.3% |
| Operating Margin | -321.3% | 0.2% | -18.6% | -4.6% | -3.2% |
| Total Debt | $10M | $277M | $6M | $168M | $3M |
| Cash & Equiv. | $56M | $33M | $30M | $1M | $13M |
ORGN vs BIOX vs PGEN vs GEVO vs LOOP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.5 | -99.5% |
| Bioceres Crop Solut… (BIOX) | 100 | 8.8 | -91.2% |
| Precigen, Inc. (PGEN) | 100 | 120.3 | +20.3% |
| Gevo, Inc. (GEVO) | 100 | 183.0 | +83.0% |
| Loop Industries, In… (LOOP) | 100 | 10.6 | -89.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs BIOX vs PGEN vs GEVO vs LOOP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, BIOX doesn't own a clear edge in any measured category.
PGEN ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.
- -84.6% 10Y total return vs LOOP's -90.8%
- Lower volatility, beta 1.44, Low D/E 14.3%, current ratio 4.76x
- +207.4% vs ORGN's -92.8%
GEVO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
- -6.6% margin vs PGEN's -39.1%
- -1.7% ROA vs PGEN's -144.1%, ROIC -2.8% vs -152.8%
LOOP is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.89
- Beta 0.89, current ratio 3.50x
- 70.2% revenue growth vs PGEN's -36.9%
- Beta 0.89 vs BIOX's 1.94
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 70.2% revenue growth vs PGEN's -36.9% | |
| Quality / Margins | -6.6% margin vs PGEN's -39.1% | |
| Stability / Safety | Beta 0.89 vs BIOX's 1.94 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +207.4% vs ORGN's -92.8% | |
| Efficiency (ROA) | -1.7% ROA vs PGEN's -144.1%, ROIC -2.8% vs -152.8% |
ORGN vs BIOX vs PGEN vs GEVO vs LOOP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ORGN vs BIOX vs PGEN vs GEVO vs LOOP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BIOX leads in 1 of 6 categories
GEVO leads 1 • PGEN leads 1 • ORGN leads 0 • LOOP leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BIOX and LOOP each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIOX is the larger business by revenue, generating $318M annually — 50.4x PGEN's $6M. GEVO is the more profitable business, keeping -6.6% of every revenue dollar as net income compared to PGEN's -39.1%. On growth, PGEN holds the edge at +2.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $25M | $318M | $6M | $174M | $11M |
| EBITDAEarnings before interest/tax | -$70M | $21M | -$115M | $18M | $63,000 |
| Net IncomeAfter-tax profit | -$69M | -$53M | -$247M | -$11M | -$3M |
| Free Cash FlowCash after capex | -$55M | $37M | -$76M | -$35M | -$404,000 |
| Gross MarginGross profit ÷ Revenue | +1.8% | +39.1% | +23.0% | +23.4% | +96.3% |
| Operating MarginEBIT ÷ Revenue | -3.2% | +0.2% | -18.6% | -4.6% | -3.2% |
| Net MarginNet income ÷ Revenue | -2.8% | -16.6% | -39.1% | -6.6% | -24.3% |
| FCF MarginFCF ÷ Revenue | -2.2% | +11.5% | -12.0% | -19.9% | -3.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -43.2% | -16.4% | +2.1% | +47.5% | +65.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +57.7% | -37.3% | -11.7% | +3.8% | +76.0% |
Valuation Metrics
BIOX leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, BIOX's 20.0x EV/EBITDA is more attractive than GEVO's 102.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $211M | $30M | $1.2B | $493M | $68M |
| Enterprise ValueMkt cap + debt − cash | $164M | $274M | $1.2B | $659M | $58M |
| Trailing P/EPrice ÷ TTM EPS | -2.45x | -0.58x | -8.83x | -14.50x | -4.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 20.01x | — | 102.12x | — |
| Price / SalesMarket cap ÷ Revenue | 6.74x | 0.09x | 309.66x | 3.07x | 6.26x |
| Price / BookPrice ÷ Book value/share | 0.60x | 0.10x | 28.85x | 1.01x | 182.83x |
| Price / FCFMarket cap ÷ FCF | — | 0.85x | — | — | — |
Profitability & Efficiency
GEVO leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
GEVO delivers a -2.4% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-6 for PGEN. ORGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to LOOP's 8.41x. On the Piotroski fundamental quality scale (0–9), GEVO scores 4/9 vs ORGN's 2/9, reflecting mixed financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.9% | -16.7% | -5.9% | -2.4% | -2.1% |
| ROA (TTM)Return on assets | -19.7% | -6.7% | -144.1% | -1.7% | -24.0% |
| ROICReturn on invested capital | -19.6% | -0.5% | -152.8% | -2.8% | -8.7% |
| ROCEReturn on capital employed | -20.8% | -0.8% | -107.2% | -3.1% | -35.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 3 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.94x | 0.14x | 0.36x | 8.41x |
| Net DebtTotal debt minus cash | -$47M | $244M | -$24M | $166M | -$10M |
| Cash & Equiv.Liquid assets | $56M | $33M | $30M | $1M | $13M |
| Total DebtShort + long-term debt | $10M | $277M | $6M | $168M | $3M |
| Interest CoverageEBIT ÷ Interest expense | -417.10x | -0.07x | -273.83x | -0.04x | -0.69x |
Total Returns (Dividends Reinvested)
PGEN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PGEN five years ago would be worth $6,346 today (with dividends reinvested), compared to $48 for ORGN. Over the past 12 months, PGEN leads with a +207.4% total return vs ORGN's -92.8%. The 3-year compound annual growth rate (CAGR) favors PGEN at 49.2% vs ORGN's -77.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -79.9% | -65.0% | -3.0% | -1.5% | +38.9% |
| 1-Year ReturnPast 12 months | -92.8% | -88.5% | +207.4% | +88.0% | +42.4% |
| 3-Year ReturnCumulative with dividends | -98.9% | -95.3% | +232.0% | +65.0% | -55.2% |
| 5-Year ReturnCumulative with dividends | -99.5% | -96.8% | -36.5% | -65.2% | -83.5% |
| 10-Year ReturnCumulative with dividends | -99.5% | -95.1% | -84.6% | -98.6% | -90.8% |
| CAGR (3Y)Annualised 3-year return | -77.7% | -64.0% | +49.2% | +18.2% | -23.5% |
Risk & Volatility
Evenly matched — PGEN and LOOP each lead in 1 of 2 comparable metrics.
Risk & Volatility
LOOP is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PGEN currently trades 79.3% from its 52-week high vs ORGN's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 1.89x | 1.43x | 1.55x | 0.85x |
| 52-Week HighHighest price in past year | $28.49 | $5.18 | $5.23 | $2.97 | $2.29 |
| 52-Week LowLowest price in past year | $0.20 | $0.35 | $1.23 | $1.01 | $0.85 |
| % of 52W HighCurrent price vs 52-week peak | +5.0% | +9.1% | +79.3% | +68.4% | +61.6% |
| RSI (14)Momentum oscillator 0–100 | 30.7 | 44.6 | 62.7 | 53.5 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 161K | 804K | 4.3M | 4.5M | 74K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ORGN as "Buy", PGEN as "Buy", GEVO as "Buy". Consensus price targets imply 6238.0% upside for ORGN (target: $90) vs 44.6% for PGEN (target: $6).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | $90.00 | — | $6.00 | $3.50 | — |
| # AnalystsCovering analysts | 6 | — | 16 | 14 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.1% | 0.0% | 0.0% | 0.0% |
BIOX leads in 1 of 6 categories (Valuation Metrics). GEVO leads in 1 (Profitability & Efficiency). 2 tied.
ORGN vs BIOX vs PGEN vs GEVO vs LOOP: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ORGN or BIOX or PGEN or GEVO or LOOP a better buy right now?
For growth investors, Loop Industries, Inc.
(LOOP) is the stronger pick with 70. 2% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ORGN or BIOX or PGEN or GEVO or LOOP?
Over the past 5 years, Precigen, Inc.
(PGEN) delivered a total return of -36. 5%, compared to -99. 5% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: PGEN returned -84. 4% versus ORGN's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ORGN or BIOX or PGEN or GEVO or LOOP?
By beta (market sensitivity over 5 years), Loop Industries, Inc.
(LOOP) is the lower-risk stock at 0. 85β versus Bioceres Crop Solutions Corp. 's 1. 89β — meaning BIOX is approximately 124% more volatile than LOOP relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 3% versus 8% for Loop Industries, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ORGN or BIOX or PGEN or GEVO or LOOP?
By revenue growth (latest reported year), Loop Industries, Inc.
(LOOP) is pulling ahead at 70. 2% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ORGN or BIOX or PGEN or GEVO or LOOP?
Bioceres Crop Solutions Corp.
(BIOX) is the more profitable company, earning -15. 5% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps -15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIOX leads at -1. 1% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — LOOP leads at 95. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ORGN or BIOX or PGEN or GEVO or LOOP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ORGN or BIOX or PGEN or GEVO or LOOP better for a retirement portfolio?
For long-horizon retirement investors, Loop Industries, Inc.
(LOOP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 85)). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LOOP: -90. 5%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ORGN and BIOX and PGEN and GEVO and LOOP?
These companies operate in different sectors (ORGN (Basic Materials) and BIOX (Basic Materials) and PGEN (Healthcare) and GEVO (Basic Materials) and LOOP (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ORGN is a small-cap quality compounder stock; BIOX is a small-cap quality compounder stock; PGEN is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock; LOOP is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.